Navigation Links
Director of Berman Institute comments on FDA Approval of first human embryonic stem cell trial
Date:1/23/2009

"The report today that the FDA has approved the first human clinical trial of an embryonic stem cell-based intervention raises important ethical considerations, but not only, or even primarily, because what is at issue is an embryonic stem cell-based intervention. Although deep-seated disagreements about the ethics of embryo research surround the interest in this study, we need to focus as well on this being the first human trial of its kind. Any "first in human beings" medical experiment requires the highest level of moral scrutiny and oversight. At this point it is critical that every effort be made to protect the welfare and rights of the patients who will be approached to be these human subjects. A good place to start would be by NOT referring to this study as a trial of a stem cell-based therapy, as Geron has described it, but rather as a stem cell-based intervention whose therapeutic benefits in humans has not yet been studied. It is also important to emphasize that this trial offers little prospect of clinical improvement to the very first patients who will participate in the safety phase of the research."


'/>"/>

Contact: Ralph Loglisci
RalphL@jhu.edu
410-625-7872
Johns Hopkins Berman Institute of Bioethics
Source:Eurekalert

Page: 1

Related biology news :

1. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
2. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
3. Director of National Intelligence to Speak at Conference
4. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
5. Director of National Intelligence to Speak at Conference
6. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
7. Ingram Micro to Distribute New Fujitsu Biometric Login Products for Novell eDirectory in United States
8. Solidus Networks, Inc. Seats New Board of Directors
9. Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR
10. Julia Zeitlinger selected for NIH Directors New Innovator Award
11. bioMETRX, Inc. Welcomes Residential and Commercial Security Expert to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Oxford Gene Technology (OGT), ... panel range with the launch of the SureSeq myPanel™ NGS ... variants in familial hypercholesterolemia (FH). The panel delivers single nucleotide ... single small panel and allows customisation by ,mix and match, ... for LDLR , P C SK9 ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... the World Technology Awards. uBiome is one of just six company finalists in ... , In addition to uBiome, companies nominated as finalists in this year’s awards ...
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
Breaking Biology Technology: